Urea cycle disorders (UCDs) are a group of genetic diseases that disrupt the body's ability to eliminate ammonia, a toxic byproduct of protein metabolism. A key player in this intricate metabolic pathway is N-Carbamyl-L-Glutamic Acid (CAS 1188-38-1). As a potent activator of carbamoyl phosphate synthetase 1 (CPS1), this compound plays a crucial role in facilitating the efficient conversion of ammonia into urea, thereby preventing dangerous ammonia accumulation in the blood (hyperammonemia).

For researchers and pharmaceutical formulators, understanding the biological significance of N-Carbamyl-L-Glutamic Acid is paramount when considering its use. Its ability to enhance CPS1 activity makes it an invaluable therapeutic agent, particularly for conditions like N-acetylglutamate synthase (NAGS) deficiency, where the body's natural production of this activator is impaired. This underscores the importance of sourcing a pure and reliable supply of this chemical.

As a leading manufacturer and supplier in China, we provide high-quality N-Carbamyl-L-Glutamic Acid that meets the rigorous demands of the pharmaceutical industry. Our commitment to quality ensures that the product you purchase is suitable for therapeutic applications. We understand that consistent availability and competitive pricing are key concerns for our B2B clients. Therefore, we offer flexible procurement options and encourage you to buy N-Carbamyl-L-Glutamic Acid in quantities that suit your needs.

For those seeking to incorporate this vital compound into their research or product development, our team is readily available to provide detailed specifications, safety data, and assistance with your order. Exploring our catalog to order N-Carbamyl-L-Glutamic Acid means partnering with a trusted source committed to supporting advancements in metabolic disorder treatment. We are dedicated to being your go-to pharmaceutical intermediate supplier.